{"id":22995,"date":"2024-03-06T16:02:46","date_gmt":"2024-03-06T15:02:46","guid":{"rendered":"https:\/\/ggba.swiss\/arga-medtech-secures-eur-54-million-towards-its-atrial-fibrillation-treatment\/"},"modified":"2024-03-06T16:05:57","modified_gmt":"2024-03-06T15:05:57","slug":"arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/","title":{"rendered":"Arg\u00e1 Medtech l\u00e8ve EUR 54 millions pour son traitement de la fibrillation auriculaire"},"content":{"rendered":"\n

Bas\u00e9e sur le campus des sciences de la vie du Biop\u00f4le<\/a> \u00e0 Lausanne, avec des activit\u00e9s \u00e0 San Diego, en Californie, Arg\u00e1 Medtech<\/a> est \u00e0 la pointe du d\u00e9veloppement de traitements de nouvelle g\u00e9n\u00e9ration pour les arythmies cardiaques, en particulier la fibrillation auriculaire (FA). La technologie Coherent Sine-Burst Electroporation\u2122 (CSE\u2122) de la soci\u00e9t\u00e9 repr\u00e9sente une avanc\u00e9e significative dans le domaine des interventions chirurgicales peu invasives pour le traitement de la FA.<\/p>\n\n\n\n

Le nouveau syst\u00e8me d’ablation CSE\u2122 d’Arg\u00e1 Medtech offre aux \u00e9lectrophysiologistes une capacit\u00e9 in\u00e9gal\u00e9e de traiter efficacement et en toute s\u00e9curit\u00e9 diverses r\u00e9gions du c\u0153ur \u00e0 l’aide d’un cath\u00e9ter polyvalent tout-en-un. Cette technologie garantit non seulement une m\u00e9thode de traitement plus s\u00fbre en minimisant le risque de l\u00e9sions thermiques des tissus environnants, mais simplifie \u00e9galement la proc\u00e9dure, r\u00e9duisant ainsi la dur\u00e9e globale du traitement et les co\u00fbts associ\u00e9s.<\/p>\n\n\n\n

La soci\u00e9t\u00e9 a r\u00e9cemment annonc\u00e9 la cl\u00f4ture d’un cycle de financement de s\u00e9rie B de EUR 54 millions. Cette \u00e9tape financi\u00e8re importante, men\u00e9e par un consortium d’investisseurs comprenant Advent Life Sciences (Royaume-Uni), Earlybird Health (Allemagne), Gilde Healthcare (Pays-Bas) et un investisseur strat\u00e9gique dont l’identit\u00e9 n’a pas \u00e9t\u00e9 r\u00e9v\u00e9l\u00e9e, a pour but de propulser les \u00e9tudes cliniques du syst\u00e8me d’ablation cardiaque innovant d’Arg\u00e1 Medtech \u00e0 la fois aux \u00c9tats-Unis et dans l’Union europ\u00e9enne.<\/p>\n\n\n\n

David Neale, CEO d’Arg\u00e1 Medtech, a exprim\u00e9 sa gratitude pour le soutien des investisseurs, soulignant leur vision commune de r\u00e9volutionner le traitement de l’ablation de la fibrillation auriculaire. Les fonds faciliteront principalement l’ex\u00e9cution d’une \u00e9tude d’exemption de dispositif exp\u00e9rimental (IDE) aux \u00c9tats-Unis et d’une \u00e9tude de marquage CE dans l’UE, ouvrant la voie \u00e0 une accessibilit\u00e9 plus large de leur syst\u00e8me d’ablation par champ puls\u00e9 CSE\u2122 (PFA).<\/p>\n\n\n\n

Une alternative plus s\u00fbre et plus pr\u00e9cise pour les patients victimes d’un AVC<\/h4>\n\n\n\n

Le financement soutient \u00e9galement l’expansion des op\u00e9rations d’Arg\u00e1 Medtech \u00e0 San Diego, anticipant l’augmentation des activit\u00e9s cliniques aux \u00c9tats-Unis. En outre, cette s\u00e9rie B s’appuie sur l’\u00e9lan donn\u00e9 par l’entreprise \u00e0 la suite d’une premi\u00e8re \u00e9tude sur 48 patients en Europe, qui a d\u00e9montr\u00e9 l’efficacit\u00e9 de la plateforme dans le traitement de la fibrillation auriculaire.<\/p>\n\n\n\n

La fibrillation auriculaire, qui est l’arythmie cardiaque la plus r\u00e9pandue dans le monde, augmente consid\u00e9rablement le risque d’accident vasculaire c\u00e9r\u00e9bral chez les patients. Les m\u00e9thodes traditionnelles d’ablation par \u00e9nergie thermique, bien qu’efficaces, comportent des risques plus \u00e9lev\u00e9s que l’apport d’\u00e9nergie par PFA. La solution d’Arg\u00e1 Medtech vise \u00e0 offrir une alternative plus s\u00fbre et plus pr\u00e9cise aux millions de personnes touch\u00e9es par cette maladie.<\/p>\n","protected":false},"excerpt":{"rendered":"

Arg\u00e1 Medtech, une soci\u00e9t\u00e9 pionni\u00e8re dans la technologie de l’ablation par champ puls\u00e9, a cl\u00f4tur\u00e9 son tour de table de s\u00e9rie B d’un montant de EUR 54 millions.<\/p>\n","protected":false},"author":6,"featured_media":22992,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1148,1181,1163,1141,1168],"class_list":["post-22995","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-financing-fr-2","tag-medical-devices-fr","tag-medtech-fr-2","tag-personalized-medicine-fr-2","tag-technology-park-fr-2"],"acf":[],"yoast_head":"\nArg\u00e1 Medtech l\u00e8ve EUR 54 Mpour traiter la fibrillation auriculaire<\/title>\n<meta name=\"description\" content=\"Arg\u00e1 Medtech, une soci\u00e9t\u00e9 pionni\u00e8re dans l'ablation par champ puls\u00e9, a cl\u00f4tur\u00e9 son tour de table d'un montant de EUR 54 millions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arg\u00e1 Medtech l\u00e8ve EUR 54 Mpour traiter la fibrillation auriculaire\" \/>\n<meta property=\"og:description\" content=\"Arg\u00e1 Medtech, une soci\u00e9t\u00e9 pionni\u00e8re dans l'ablation par champ puls\u00e9, a cl\u00f4tur\u00e9 son tour de table d'un montant de EUR 54 millions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-06T15:02:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-06T15:05:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Arga-Medtech-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Arg\u00e1 Medtech l\u00e8ve EUR 54 millions pour son traitement de la fibrillation auriculaire\",\"datePublished\":\"2024-03-06T15:02:46+00:00\",\"dateModified\":\"2024-03-06T15:05:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/\"},\"wordCount\":502,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Arga-Medtech-1180x811-1.jpeg\",\"keywords\":[\"Financing\",\"Medical Devices\",\"Medtech\",\"Personalized Medicine\",\"Technology Park\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/\",\"name\":\"Arg\u00e1 Medtech l\u00e8ve EUR 54 Mpour traiter la fibrillation auriculaire\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Arga-Medtech-1180x811-1.jpeg\",\"datePublished\":\"2024-03-06T15:02:46+00:00\",\"dateModified\":\"2024-03-06T15:05:57+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Arg\u00e1 Medtech, une soci\u00e9t\u00e9 pionni\u00e8re dans l'ablation par champ puls\u00e9, a cl\u00f4tur\u00e9 son tour de table d'un montant de EUR 54 millions.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Arga-Medtech-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Arga-Medtech-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"La technologie d'Arg\u00e1 Medtech mesure l'innocuit\u00e9 et l'efficacit\u00e9 de l'\u00e9lectroporation par ondes sinuso\u00efdales coh\u00e9rentes chez les patients atteints de fibrillation auriculaire. | \u00a9 Arg\u00e1 Medtech\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arg\u00e1 Medtech l\u00e8ve EUR 54 millions pour son traitement de la fibrillation auriculaire\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arg\u00e1 Medtech l\u00e8ve EUR 54 Mpour traiter la fibrillation auriculaire","description":"Arg\u00e1 Medtech, une soci\u00e9t\u00e9 pionni\u00e8re dans l'ablation par champ puls\u00e9, a cl\u00f4tur\u00e9 son tour de table d'un montant de EUR 54 millions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/","og_locale":"fr_FR","og_type":"article","og_title":"Arg\u00e1 Medtech l\u00e8ve EUR 54 Mpour traiter la fibrillation auriculaire","og_description":"Arg\u00e1 Medtech, une soci\u00e9t\u00e9 pionni\u00e8re dans l'ablation par champ puls\u00e9, a cl\u00f4tur\u00e9 son tour de table d'un montant de EUR 54 millions.","og_url":"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-03-06T15:02:46+00:00","article_modified_time":"2024-03-06T15:05:57+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Arga-Medtech-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Arg\u00e1 Medtech l\u00e8ve EUR 54 millions pour son traitement de la fibrillation auriculaire","datePublished":"2024-03-06T15:02:46+00:00","dateModified":"2024-03-06T15:05:57+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/"},"wordCount":502,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Arga-Medtech-1180x811-1.jpeg","keywords":["Financing","Medical Devices","Medtech","Personalized Medicine","Technology Park"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/","url":"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/","name":"Arg\u00e1 Medtech l\u00e8ve EUR 54 Mpour traiter la fibrillation auriculaire","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Arga-Medtech-1180x811-1.jpeg","datePublished":"2024-03-06T15:02:46+00:00","dateModified":"2024-03-06T15:05:57+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Arg\u00e1 Medtech, une soci\u00e9t\u00e9 pionni\u00e8re dans l'ablation par champ puls\u00e9, a cl\u00f4tur\u00e9 son tour de table d'un montant de EUR 54 millions.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Arga-Medtech-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Arga-Medtech-1180x811-1.jpeg","width":1180,"height":811,"caption":"La technologie d'Arg\u00e1 Medtech mesure l'innocuit\u00e9 et l'efficacit\u00e9 de l'\u00e9lectroporation par ondes sinuso\u00efdales coh\u00e9rentes chez les patients atteints de fibrillation auriculaire. | \u00a9 Arg\u00e1 Medtech"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/arga-medtech-leve-eur-54-millions-pour-son-traitement-de-la-fibrillation-auriculaire\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Arg\u00e1 Medtech l\u00e8ve EUR 54 millions pour son traitement de la fibrillation auriculaire"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/22995","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=22995"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/22995\/revisions"}],"predecessor-version":[{"id":22997,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/22995\/revisions\/22997"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/22992"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=22995"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=22995"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=22995"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}